Cardiomyocyte targeted Curcumin/CMC-peptide increases bioavailability of the drug.
Curcumin nanoparticle regresses cardiac hypertrophy by reducing myocyte apoptosis.
Targeted Curcumin shows higher efficacy over free Curcumin to regress hypertrophy.
Curcumin modulates p300-HAT axis to facilitate p53 degradation.